La Prof.ª Lina Badimon, vicepresidenta de la Sociedad Española de Cardiología (SEC), participa en la sesión 'Qué hay de nuevo respecto al papel de las estatinas. Control lipídico en los pacientes de alto riesgo CV en España', perteneciente a la 'Jornada Galáctica sobre Guías de Lípidos y objetivos a alcanzar en los pacientes de más alto riesgo cardiovascular' (Málaga, 4-5 abril, 2014).
Accede a la jornada completa en http://guiaslipidos.secardiologia.es
Effects of statins beyond hepatic cholesterol synthesis regulation
1. Effects of statins beyond hepatic cholesterol
synthesis regulation:
Managing Cardiovascular Risk In the 21st Century
Lina Badimon
Barcelona CardiovascularScienceCenter (CSIC-ICCC)
Hospital de la Santa Creui Sant Pau
Málaga, April 2014
2. Cholesterol and Lipoproteins
in CoronaryArteryDisease
Bloodcholesterol pool
•Vesselwalllipid pool
•Cellulareffects
Intestinal CholesterolAbsorption
HepaticCholesterolSynthesis
Badimon L. 2014
3. Cholesterol and Lipoproteins
in CoronaryArteryDisease
Bloodcholesterol pool
•Vesselwalllipid pool
•Cellulareffects
Intestinal CholesterolAbsorption
HepaticCholesterolSynthesis
HYPERCHOLESTEROLEMIA ATHEROSCLEROSIS
Badimon L. 2014
4. Cholesterol and Lipoproteins
in CoronaryArteryDisease
Bloodcholesterol pool
•Vesselwalllipid pool
•Cellulareffects
Intestinal CholesterolAbsorption
HepaticCholesterolSynthesis
treatment
Badimon L. 2014
5. Cholesterol and Lipoproteins
in CoronaryArteryDisease
Bloodcholesterol pool
•Vesselwalllipid pool
•Cellulareffects
Intestinal CholesterolAbsorption
HepaticCholesterolSynthesis
treatment
Badimon L. 2014
6. Cholesterol and Lipoproteins
in CoronaryArteryDisease
bloodcholesterol pool
•Vesselwalllipid pool
•Cellulareffects
Intestinal CholesterolAbsorption
HepaticCholesterolSynthesis
treatment
Badimon L. 2014
9. Alonso R et al Atherosclerosis 2001;
Martinez J et al ATVB 2001.
Albert MA, et al. JAMA. 2001;
Ridker PM, et al. Circulation. 2001;
Crea F, et al. Clin Cardiol.2002;
Semb AG. JACC 203;
Nissen SE, et al. JAMA. 2004;
AlfonJ JTH 1999;
Casani JTH 2005;
Molins B ATVB 2008;
Molins B ATVB 2010
Llorente-Cortés V, et al. Circulation 2004
ICCC-Badimon L. 2014
10. Padro T,..Badimon L. Cardiovasc Res 2007
agLDL impair migration of human coronary VSMC
VSMC
+ /- agLDL
(16 hours)
double sided scrape-wound
0
20
40
60
80
100
0 2 4 6 8 12
Time (hours)
%regeneratedarea
control
agLDL
agLDL
control
8h6h
12h6h
12h
0h
ICCC-Badimon L. 2014
11. 0 hours
A
8 hours after wounding
C
nLDL
agLDL
- rosuvastatin
B C
D E
F G
+ rosuvastatin
0
20
40
60
80
100
0 2 4 6 8 12
woundcoverage(%)
C
C+R
nLDL
nLDL+R
C
C+R
agLDL
agLDL+R
0
20
40
60
80
100
woundcoverage(%)
0 2 4 6 8 12
nLDL agLDL
hours hours
STATINS REVERT THE
PATHOLOGICAL EFFECTS
OF LDL IN THE VESSEL WALL
PadroT,LuganoR,GarciaM,BadimonL.PlosOne2012
ICCC-Badimon L. 2014
12. PROTEOMIC INVESTIGATION ON STATIN EFFECTS ON HUMAN CORONARY VASCULAR CELLS
PadroT,LuganoR,GarciaM,BadimonL.PlosOne2012
ICCC-Badimon L. 2014
MRLC
13. MolinsB, Peña E, PadroT, CasaniL, MendietaC, Badimon L. ATVB 2010
AHA- KARL LINK AWARD – BEST ARTICLE ON THROMBOSIS OF 2010
platelet surface GRP78 (red)
platelet membrane receptor GPIIIa (green).
Control
Resting
Platelets
Control
Sheared
(1500/s)
Platelets
Rosuvastatin-
treated
Sheared
(1500/s)
Platelets
GRP78 IN HUMAN PLATELETS
control
Rosuvastatin 8 M
0
2000
4000
6000
8000
10000
12000
250 s-1 1500 s-1
Platelet Adhesion
*
*
MPD(m2/field)
1500 s-1
Urea-soluble fraction
(membrane/ cytoskeleton)
Tris-soluble fraction
(cytoplasm)
1500 s-1 +
rosuvastain
1 2 3
PROTEOMIC IDENTIFICATION OF GRP78
ICCC-Badimon L. 2014
14. Sardella G, Catheter CardiovascInterv. 2012
ROMA TRIAL: ROSUVASTATIN PRETREATMENT IN ELECTIVE PCI
Statin-naif pts/40mg rosu/24h pre-PCI
P>0.001
ICCC-Badimon L. 2014
15. Norris DM, Cardiol Rev 2012 Nov 20(6) 319-24
StatinLoadingBeforePercutaneousCoronaryIntervention
to Reduce PeriproceduralMyocardialInfarction
ICCC-Badimon L. 2014